AIRS Medical secures a strategic growth investment to advance AI-powered MRI technology

AIRS Medical, the AI medical imaging company behind the SwiftMR and SwiftSight platforms, has announced a strategic growth investment from TA Associates, one of the world’s leading global private equity firms with $65 billion in capital raised since 1968. The investment will accelerate global expansion and drive continued innovation in AI-powered MRI solutions at a time when imaging departments worldwide are under growing pressure to do more with existing infrastructure.

For radiographers and radiologists managing MRI capacity constraints, the timing is significant. Imaging demand continues to outpace available scanner time across health systems, and AIRS Medical has built its commercial momentum squarely around that challenge. The company’s flagship solution, SwiftMR, uses deep learning to reduce MRI acquisition times while maintaining or improving image quality — enabling departments to increase throughput without adding hardware or headcount.

The scale of adoption speaks for itself. AIRS Medical currently supports more than 1,700 healthcare institutions across over 40 countries, with its AI technologies applied to more than six million MRI examinations annually. Deployments span leading academic medical centres, health systems and outpatient imaging networks, including Northwestern Medicine and MedStar Georgetown University Hospital in the United States. The company’s vendor-neutral platform operates across 1.5T and 3.0T MRI systems from all major manufacturers, removing a common barrier to AI adoption in mixed-vendor environments.

Alongside SwiftMR, the company’s SwiftSight platform addresses the downstream challenge of MRI quantification and structured reporting, offering departments a unified solution from image acquisition through clinical interpretation. Together, the two solutions represent a comprehensive approach to MRI workflow optimization that extends beyond image quality into operational performance and clinical decision support.

Jason Park, chief executive officer of AIRS Medical, said the investment will be directed towards accelerating product innovation and expanding the company’s international footprint. “Demand for technologies that improve MRI efficiency and expand patient access continues to grow globally,” he noted. “With TA’s support, we will continue helping healthcare providers unlock greater value from their existing MRI infrastructure.”

Edward Sippel, managing director and head of TA Asia Pacific, highlighted AIRS Medical’s category leadership as a key factor in the investment decision. “MRI plays a critical role in modern healthcare, yet providers around the world continue to face growing demand, capacity constraints and operational challenges,” he said. “We believe AIRS Medical’s leadership team, strong track record of innovation, and clear category leadership in AI-powered MRI position the company well to help address these challenges.”

Crucially, the investment was made with AIRS Medical operating profitably — a distinction that sets it apart from many AI healthcare companies still in pre-revenue or early commercial stages. For imaging departments evaluating long-term technology partners, that financial stability, combined with demonstrated clinical validation and global deployment scale, offers a level of confidence that funding announcements alone cannot provide.

For more information, visit airsmed.com.

This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine.